

BRAIN Biotech AG

Creating a #BiobasedFuture



Investor Relations Presentation 2022

Zwingenberg, January 2022



Safe Harbor Statement

This document may contain forward-looking statements. These forward-looking statements are subject to risks and uncertainties, as they relate to future events and are based on current assumptions of the Company, which may not occur at all in the future or may not occur as assumed. They do not represent a guarantee for future results or performance of the Company, and the development of economic and legal conditions may materially differ from the information expressed or implied in the forward-looking statements.

The Company assumes no obligation to update or revise any forward-looking statement contained herein or to adapt them to future events or developments. The information contained in this document has not been independently verified. No representation or warranty expressed or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinion contained herein. The Company or any of its shareholders, affiliates, advisors, employees or representatives shall have no liability whatsoever (in negligence or otherwise) for any loss arising from any use of this document or its content or otherwise arising in connection with this document.

By accepting this presentation you acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the Company's business.

This presentation speaks as of January 17th, 2022. Neither the delivery of this presentation nor any further discussions of the Company with any of the recipients shall, under any circumstances, create any implication that there has been no change in the affairs of the Company since such date. The term "BRAIN", as used in this presentation means Brain Biotech AG and its affiliates, if not otherwise specified.

BRAIN at a Glance

~ €38m

'20/'21 Revenues

> 28

Years of Experience

~ 320

Employees

> 230

Specialty B2B Products

> 150

Industrial Partnerships

2016

Listed, Frankfurt Prime Standard

Creating Breakthrough Bioproducts & Solutions for Nutrition, Health and Environment

Industrial Biotech
(white)



Three
Product Platforms



Enzymes



Microorganisms



Bioactive
Natural
Compounds

From Lab to Production

Mission & Vision

“Mission is what an organization is or does. Vision is what an organization desires to become”

Mission

Creating Breakthrough Bioproducts and Solutions for Nutrition, Health and the Environment

Vision

We will be the **Industrial/White Biotech Specialists** in finding and exploring high-value niches in our products business and novel solutions in our science business. We will be much more agile than others and will always look to produce products in-house or with partners



When Should You **#Think BRAIN?** in the center of mega-trends

Health & Nutrition

Vegan & Vegetarian Food: Alternative Protein Base
(Precise Fermentation / Microbial Production Hosts)

Healthy & Better Tasting Beverages:
Natural Flavors (like NatBev 1 & 2)

All Natural Preservatives:
Perillic Active from Fermented Orange Oils

Calorie-Free Natural Sweeteners:
Plantbased Sweeteners (Brazzein, Sweet Box)

Healthy Food:
reduction of salt in foods (SALT-1)

Biological Wound Care:
Biological Wound Management (Aurase/SolasCure)

Creating a BiobasedFuture

Genome Engineering:
Novel Non-Cas9 Nucleases

Biological Production:
Enzymes & Large Scale Fermentation


Environment

BioMining:
Sustainable Metal Extraction (Urban Mining)

Biological Production:
Enzymes & Large Scale Fermentation

Making Waste Valuable:
Fermented Food from Side Streams
Microbial CO₂ Usage


This is BRAIN



*FY '20/'21

BRAIN Group

Value Creation & Synergies



- Enzymes: integrated value chain from lab to production
- Industrial Scale-up and application know-how
- In-house strain optimization & development
- Customer strain development & Bio Process
- Variable scientist pool for internal/external projects
- TMS creates strong industrial partner network
- Utilize TMS knowledge for Incubator Projects and alternative use-cases
- Shared corporate services & financing

- 1 Products Business**
- Focus on high-growth & high-margin niches
 - Re-shape from a purchase for resale to an own production model
 - Strong target markets with healthy sales and margin growth in F&B, healthcare and environment

- 2 TMS /Libraries Business**
- TMS: longer term contract research programs (average duration 2 years); strong industrial partner network; rich pipeline of possible new projects; “CRISPR for You”
 - Libraries: main customers from food, pharma & cosmetics industries. Access fees and upside from milestone payments / license income

- 3 Incubator**
- Focus on breakthrough products with a strong societal impact
 - Significant value creation from development to launch
 - De-risk R&D with partners and public funding
 - Dynamic pipeline: mature products marketed, new products will enter

- 4 SolasCure**
- Innovative enzymatic wound care
 - Spin-out, 41% participation
 - IP for enzyme Aurase owned by BRAIN
 - All options open to crystalize value from stake-holding

Six Strong Reasons to Invest in BRAIN Biotech AG

1. **Mega-trends / UN-SDGs:** our products address the big societal topics – nutrition, health & the environment. We address at least 5 SDGs directly
2. **Incubator products:** big upsides in our breakthrough inventions. BEC/BMC potential to be transformational.
3. **BioIndustrial:** BRAIN is very well positioned to capture high-growth and high-margin niches in its products businesses. We will re-shape our BioIndustrial business and move from a purchase for resale model to an own production model, this creates significant margin and therefore value upside
4. **Strong target markets:** solid target markets for our services & products with CAGRs above GDP and strong EBITDA margin levels also allow BRAIN to harvest healthy sales and margin growth
5. **Value accretive M&A:** space for bolt-on acquisition to accelerate growth with the possibility for transformational growth through larger M&A
6. **R&D:** ability to fund research with partners and from governmental grants to de-risks our own R&D effort and preserve valuable cash

Six Major Triggers driving Revenue and Margin Growth

BRAIN: At the Heart of UN SUSTAINABLE DEVELOPMENT GOALS

Our Products & Solutions address at least five goals directly

WE SUPPORT



Since 2021 we have been committed to the UN Global Compact corporate responsibility initiative and its principles in the areas of human rights, labour, the environment and anti-corruption.

- Natural compounds for food preservation

- Sugar replacement / Sugar taste enhancer
- Salt replacement / Salt taste enhancer
- Natural aromas
- Wound treatment
- Bioactive plant cosmetics



- Green mining

- Green Mining
- Urban Mining

- Biological production
- Improving production efficiencies
- Fermented food from sidestreams
- Microbial CO₂ Usage


Five Strategic Initiatives Centered Around our Core Values

5 Continuous Corp. Culture Development

- Can do and high ethics culture
- Talent management
- Innovation is our passion
- Teamwork is our basis
- Sustainability as a guiding principal

4 Accretive M&A

- Successful track record of integrating acquired entities
- Further build with bolt-on acquisitions
- Transformational M&A in adjacencies



1 Profitable Top Line Growth

- Excel in specialty niches with high margins
- Selectively grow outside of Europe
- Always look for ways to produce ourselves

2 Innovation Pipeline Management


- Balanced portfolio across markets and technologies
- Breakthrough solutions for big challenges for accelerated growth
- Key customer and application focus

3 Continuous Productivity Improvements

- Strain development
- Focus on working capital efficiencies, cost improvements and free cash flow
- Group revenue synergies
- Bio-Informatics

Our Incubator

rising pipeline valuation



- Projects Green Metal Mining, Sweet Taste Enhancer and CO₂ moved to TMS business, fully funded programs
- Projects Salt-E, Fresco shelved, searching for partners
- New enzymes now part of BioIndustrial regular product development, see page 10

Progress since CMD '20, update '08/21

- Programs without contractually bound partners are marked red by default
- Contractual, technology or registration hurdles still need attention
- Phase 1 has been successfully completed but contract negotiations for the next development phase are progressing but not yet finalized

*1: BRAIN-Group rNPV FCF+TV: Small < €5M, Medium €5M - €15M, Large: €15M+
 *2: Prod: Product sales. Fee: Research fee income. MSP: Milestone payments. Lic: License/royalty payments Tec: Tech fees Prof: Entity formation or profit participation
 *3: B/A: BioActives, E/P: Enzymes and proteins, M/O: Microorganisms/starter cultures
 ND: not disclosed



Management & Employee Incentives

Since the IPO BRAIN Biotech AG's board as well as management compensation has been closely linked and aligned with shareholder interests

Executive Board

- fixed salary
- variable component based on individual quantitative & qualitative targets
- stock component, see ESOP

ESOP, Employee Stock Ownership Program

- Since June 2018
- Board, managers and employees
- Incentive and retainer
- Details: see appendix

CoPerBo, Corporate Performance Bonus

- Since FY 2015/16
- Applied for employees at BRAIN Zwingenberg
- Partially share prices based
- Details: see appendix

Specific Incentives at Daughter Companies

- See appendix

Financial Highlights 12M FY 2020/21 at a Glance

Strong BioIndustrial (ex WBT), sequentially improving BioScience

| (in € thousand) | 12M 2020/21 | 12M 2019/20 | Growth | Organic Growth | Q4 2020/21 | Q4 2019/20 | Growth | Organic Growth | Comment |
|---------------------------------|----------------|----------------|--------|-------------------|---------------|---------------|---------|-------------------|--|
| Revenues | 38,389 | 38,225 | 0.4% | -5.2% | 10,545 | 8,671 | 21.6% | 15.1% | |
| BioScience | 10,313 | 13,230 | -22.1% | -22.1% | 2,897 | 2,754 | 5.2% | 5.2% | strong sequential improvement Milestones 680K 12M 20/21 Milestones 1.2 Mio 12M 19/20 |
| BioIndustrial | 28,236 | 25,081 | 12.6% | 3.9% | 7,670 | 5,954 | 28.8% | 19.4% | all solid growth, except WBT |
| Total operating performance (1) | 40,731 | 39,238 | 3.8% | -4.1% | 10,766 | 8,928 | 20.6% | 4.7% | |
| Adjusted EBITDA (2) | -2,089 | -2,018 | -3.5% | -10.5% | 148 | -1,465 | 110.1% | 112.8% | (-) EUR 989K ESOP 12M (-) EUR 313K M&A Cost 12M (+) EUR 858K Badwill |
| EBITDA | -2,533 | -3,876 | 34.6% | 8.9% | -472 | -2,970 | 84.1% | 56.5% | |
| EBIT | -6,548 | -8,229 | 20.4% | 8.7% | -1,539 | -4,718 | 67.4% | 50.7% | |
| Net Result | -4,680 | -9,017 | 48.1% | 37.4% | -1,738 | -2,910 | 40.3% | 13.3% | |
| Operating Cash Flow | -3,906 | -4,767 | 18.1% | 13.7% | -907 | 967 | -193.8% | -179.4% | |
| Cash | 24,545 | 18,943 | 29.6% | 27.9% | | | | | |

| | 12M 20/21 | 12M 19/20 | Growth | Organic Growth |
|------------------------------|-----------|-----------|--------|-------------------|
| Number of Employees | 288 | 279 | 3.2% | 1.8% |
| Material Expense Ratio | 43.9% | 43.6% | 0.3PP | -1.2PP |
| Adj. Personnel Expense Ratio | 48.2% | 46.3% | 2.0PP | 3.6PP |

➤ CRISPR investments @ 12M ~€1.5 million (within guidance)

Major Events 12M '20/21:




- **BioSun** now consolidated for three quarters, happy with development; team well integrated
- **BioIndustrial total** solid double digit growth excl. WBT
- **WBT** remains in restructuring, 12M sales ~ (-) 26%; Q4 stabilized
- **BioScience** strong sequential growth Q on Q but FY still suffering from very weak Q1 20/21 and high base Q1 19/20; lower milestones; order book keeps improving strongly, also driven by “We CRISPR for You” business
- Costs of BioSun purchase/ integration and other M&A cost EUR 313K

(1) Revenues + change in inventories + other income + R&D grants

(2) The full reconciliation from adjusted to unadjusted EBITDA can be found in the appendix

Long-Term Revenue Growth Trajectory

strong BioIndustrial driven by BioCats, L.A. Schmitt & BioSun integration



➤ We expect to go back on the growth track in FY 21/22


*purchase BioCatalysts Ltd. **divestment Monteil Cosmetics ***purchase BioSun

****BioSun integration from Q2 20/21



Adjusted EBITDA

Adjusted EBITDA 12M 20/21



➤ CRISPR investments @ 12M ~€1.5 million

- **Group** adj. EBITDA stable YoY; balancing effects of strong BioIndustrial and challenges at the BioScience segment (high YoY comparison base (especially in Q1), lower milestone payments and negative Corona effects), CRISPR investment
- **BioScience:** further sequential improvement Q on Q; last year large payments related to two projects in Q1; lower milestone payments 12M; TMS backlog keeps rising solidly
- **BioIndustrial** all group companies strong except WeissBioTech; WBT now stabilizing and new strong management team in place to revive sales growth

Cash & Cash Flow

improving OCF, lower investments as guided, solid cash position

| (in € thousand) | 12M 2020/21 | 12M 2019/20 | Growth | Q4 2020/21 | Q4 2019/20 | Growth | Comment |
|--|----------------|----------------|--------|---------------|---------------|---------|--|
| Gross Cash Flow | -5,250 | -6,056 | 13.3% | -1,189 | -1,446 | 17.7% | |
| Operating Cash Flow | -3,906 | -4,767 | 18.1% | -907 | 967 | -193.8% | |
| Investing Cash Flow | -2,180 | -4,469 | 51.2% | -181 | 79 | -329.4% | |
| Financing Cash Flow | 11,572 | 13,093 | -11.6% | 18,398 | -821 | 2341.5% | (-) purchase BioCats minority ~€4.6 Mio |
| Net change in Cash & Cash Equivalents | 5,485 | 3,857 | 42.2% | 17,310 | 225 | 7586.0% | (+) capital increase net proceeds ~€19 Mio |
| | 30.09.2021 | 30.09.2020 | | | | | |
| Cash | 24,545 | 18,943 | 29.6% | | | | |
| Equity | 41,828 | 26,143 | 60.0% | | | | |

- September capital increase guaranteed solid cash position
- EUR 7 million undrawn credit facility available on top

Covid-19 Update

TMS backlog increasing solidly, BioIndustrial strong (ex WBT)

Summary:

**BRAIN Group: some negative Covid-19 effects materialized on FY 20/21.
Now very positive trend in the BioScience business development pipeline.**

Current Disruptions: SolasCure is facing around 9 months delays in clinical trials as the relevant test centers have been closed for non Covid-19 patients. Phase 2a clinical trials (in human) started in May. Diversification of test centers started to mitigate ongoing effects of the pandemic. Lower sales volumes of enzyme products to ethanol and beer/wine producers at WeissBioTech.

Future Challenge: the Omicron variety might impose new economic insecurity and travel restrictions making deal making in BioScience again more challenging. Managing general operational challenges including selected supply chain shortages and the turnaround at WeissBioTech.

Secure:

- Health aspects
- Supply chain
- Operating business
- Future pipeline

Targets:

- Safety of employees
- Business continuity
- Minimize disruptions
- Fulfill customer contracts

Measures:

- Vaccination @ work
- Booster @ work
- Covid-19 task force
- Hygiene concept
- Corona quick testing
- Masks on premises
- Air Filters
- Personal safety supplies
- Physical distancing
- Home office
- Strict travel restrictions
- Flex work
- Digitalize workflow

Our Targets

Guidance and Mid-Term Targets

This FY Guidance

New guidance at the 3M '21/'22 reporting on February 23rd including:

- Sales Growth indication
- Ebitda Growth indication (ex CRISPR)
- Expected Growth Indication Divisions
- CAPEX guidance
- CRISPR associated costs

Mid-Term Targets, Unchanged

(issued 09/'20, 4-5 year targets)

(excluding CRISPR)

Double group revenue from base '18/19

- Double digit topline product CAGR
- Accretive M&A
- Contract research "TMS" proportionally reduced (excl. milestones)


Group adj. EBITDA margin 15% (+/- 5PP)

- Double digit fermentation production volume of customized novel enzymes
- Mid-single digit annual productivity improvements

Proportion of new product sales: ~30% of total revenues

- Continuous innovation pipeline management

Our Share Ownership*



- Number of shares: 21,847,495
- Free float of ~ 46%
- Strong long-term investor base
- ~ 8,900 shareholders
- WKN 520394 / ISIN DE0005203947
- Symbol BNN
- Prime Standard; Frankfurt/M

*November 30th, 2021

Financial Calendar



FISCAL YEAR STATEMENT

Publication of the annual report as of September 30th, 2021 (12M)

January 17th, 2022



QUARTERLY STATEMENT

Publication of the quarterly statement as of December 31st, 2021 (3M)

February 23rd, 2022



ANNUAL GENERAL MEETING

Annual General Meeting (FY 2020/21)

March 9th, 2022



HALFYEAR STATEMENT

Publication of the half year report as of March 31st, 2022 (6M)

May 30th, 2022



QUARTERLY STATEMENT

Publication of the quarterly statement as of June 30th, 2022 (9M)

August 29th, 2022

Thank you for your attention.

BRAIN Biotech AG

Darmstädter Straße 34–36

64673 Zwingenberg, Germany

+49 (0) 6251-9331-0

www.brain-biotech.com

Your contacts:

Michael Schneiders, Head of IR & Sustainability

+49 (0) 6251-9331-86

MiS@brain-biotech.com

Martina Schuster, IR

+49 (0) 6251-9331-69

MS@brain-biotech.com



@BRAINbiotech



BRAIN Biotech AG



Appendix

| | Page |
|---|------|
| Strong sustainability contributions | 23 |
| Where BRAIN can make a difference | 24 |
| Corporate Governance | 25 |
| High barriers to entry | 26 |
| NBD deep dive | 27 |
| Service business deep dive | 33 |
| Partnerships "BRAIN Inside" | 34 |
| Enzyme production, expression hosts | 36 |
| Enzyme value chain | 38 |
| SolasCure Ltd. | 39 |
| BioArchive | 40 |
| R&D/Technology Platforms | 43 |
| HR: People -- our core capital | 43 |
| Detailed management & employee incentives | 44 |
| Peers by business activity | 45 |
| Detailed financials | |
| Detailed adjusted vs. reported | 46 |
| Expenses Development | 47 |
| Adj. vs reported | 48 |
| Financial debt vs. financial liabilities | 49 |
| Balance sheet | 50 |
| M&A criteria & history | 51 |
| Management CV | 52 |
| Analyst coverage | 54 |
| Glossary | 55 |

Strong Sustainability Contributions

BRAIN is empowering the biological transformation of the industry

- Industrial biotechnology is at the heart of the Bioeconomy
- Utilize natural raw materials efficiently
- Improve industrial manufacturing processes to become more efficient and natural
- Create new biobased products
- Make consumer goods healthier and more desirable
- Move away from fossil raw materials towards sustainably produced natural resources
- Safe energy compared to chemical processes (replace high by low energy processes)
- Significantly less CO₂ emissions
- Focus areas: **nutrition, health and the environment**
- Powered by **our proprietary BioArchive**, driven by our deep R&D and process knowledge

Selected products and solutions

- **Food:** Reduce calorie density in foods by natural sweeteners while maintaining the taste profiles; reduce the salt content in food
- **Good Health:** functional probiotics, replace chemicals in cosmetics by natural compounds; treatment of chronic wounds
- **Water/Sanitation:** replacing chemicals by biological metal extraction from e-scrap, incinerator bottom ash and other mineralic resources
- **Industry Innovation:** improving production efficiency; reducing CO₂ emissions and using CO₂ as a raw material
- **Responsible consumption:** reducing the perishability of food by bioactive antimicrobials to reduce food waste
- **Sustainable Production:** managing pollution, transforming waste streams into unprecedented value chains



Trends – Where BRAIN Can Make a Difference



Corporate Governance

Principles and policies defining BRAIN's responsible operations

- Dual German AG structure consisting of a management board and a fully independent supervisory board
- We comply with all statutory corporate governance regulations as well as the recommendations of the German Corporate Governance Code (DCGK) (exceptions specified and justified in the statement of conformity)
- BRAIN Biotech AG Code of Conduct
- BRAIN's Privacy Statement
- BRAIN's Disclosure Policy
- Quality, Health and Safety Policy
- Financial responsibility: BRAIN's operations produce added value to different stakeholders in the countries we operate
- Financial benefits are shared between, among others, suppliers, personnel, owners and the public sector
- Internal compliance: qualified internal compliance officer, permanent risk assessment, audit committee, internal audit team and risk reporting
- Monthly reporting and audit meetings with the subsidiaries
- Member of the following associations: Bio Deutschland, Dechema, IWBIO, VCI

BRAIN's most important responsibility themes: healthy & natural, product safety, responsible business conduct, workplace safety

High Barriers to entry

Our novel products & solutions are based on:

- Proprietary BioArchive with >450 person years to reproduce
- Extensive patent portfolio, around 175 patents granted and around 40 patent families
- Trade secrets
- Broad and deep technology know-how in enzymes, microorganisms and bioactive natural compounds
- Ability to express target compounds in bacteria, yeast or fungi
- Full process capabilities from the lab to production
- Strong industry partner network with over 100 partner collaborations successfully completed
- Strategic alliances for new business development
- Strong scientific and university network
- State-of-the-art technology portfolio
- Our people: first class scientists and process specialists

NBD Deep Dive, The Pipeline

Large Market Potential

Natural Beverage 2


- Partners: Japanese Beverage Company
- Scope: undisclosed, confidentially agreement
- Exclusive to partner
- Technology Platform: microorganism
- Research Business Model: milestone payments
- Commercial Model: starter cultures, production, license fee, JV an option/profit share

Brazzein Natural Sweet Solution

- Partners: BRAIN, AnalytiCon Discovery, Roquette
- Scope: development, approval and commercialization of new natural sweet solution
- Based on access to our SweetBox and Human Tongue Cell technology derived sweetener candidates
- Technology Platform: BioActive and process development
- Research Business Model: tech access fee, success fees
- Commercial Model: initial production, licensing, royalties


Aurase

- Partners: Spin-off SolasCure
- Scope: innovative wound debridement agent for the cleaning of chronic wounds
- Exclusive development through SolasCure, active enzyme IP at BRAIN
- Technology Platform: enzyme/proteins
- Research Business Model: fees, technology transfer
- Commercial Model: spin-off, exit optionality, production through BRAIN (independent from owner)



NBD Deep Dive, The Pipeline

Large Market Potential




BRAIN CRISPR Non-Cas9 Associated Nucleases (BEC/BMC)

- **Genome Editing:** directed and precise change or use of a chromosomal target in a given organism; “the power to program cells”
 - **CRISPR** = clustered regularly interspaced short palindromic repeats
 - **CAS** = CRISPR associated sequence
 - **CRISPR-Cas** systems have enabled genome editing in multiple species and provided genetic tools with speed as well as simplicity that were previously unavailable
 - **Editing** requires only two components (1. Cas nuclease 2. programmable guide RNA), and can be multiplexed for simultaneous modification of multiple sites in a single transformation event
 - Novel BRAIN CRISPR Cas system developed using metagenomics sequencing and protein engineering
 - Non-Cas9 type genome editing nuclease
 - Scarless gene modification at the single nucleotide level
 - In-house designed application tools and strategies
 - Development of customized screening cells for target identification / validation or bioactive product development / identification
 - State of the art technology for the development of high performance producer strains
 - Business Model: all option are still being evaluated, NewCo formation in 2022
- **If next development steps are successful could be transformational for BRAIN**

NBD Deep Dive, The Pipeline

Medium Market Potential




PHA 121 / Pharvaris N.V.*

- Is a clinical-stage discovery and development company, founded in 2015 (CH)
- IPO at the NASDAQ (phvs) on February 9th, 2021
- Focus: treatment of hereditary angioedema (HAE)
- **HAE:** medical disorder caused by gene mutation, which results in recurrent attacks of severe swelling (every 2-4 weeks without treatment), swelling caused by excess level of bradykinin
- **New Treatment:** novel oral bradykinin B2-receptor antagonists (PHA121)
- **Phase 2** clinical development: for on-demand HAE treatment: PHVS416 a softgel capsule formulation containing PHA121
- **Preclinical:** PHVS416 softgel capsule prophylaxis HAE and PHVS719 XR tablet prophylaxis HAE, FDA acceptance of IND application granted on April, 21st
- Commercial Model: TMS business /profit share via royalties
- Milestone payments based on clinical development, regulatory events and sales development (up to EUR 11.4 million)
- Tiered Royalty Agreement: low to medium-single digit on direct and/or indirect net sales

*Source: Pharvaris corporate presentation

NBD Deep Dive, The Pipeline

Medium Market Potential



Perillic Active


- Partners: US distribution partner contracted (non-disclosed); toll manufacturing
- Scope: nature based anti-microbial for food, feed, drinks and cosmetic applications, generated from industrial side streams; fermented orange oil
- US patent granted
- Technology Platform: BioActive
- Research Business Model: fee
- Commercial Model: JV/profit share

Gold from Waste Streams / Urban Mining

- Partners: partner search actively running for scale-up; LOI in place; non-exclusive partnerships
- Scope: CO₂ efficient biological process for gold extraction from waste streams such as e-waste, today these valuable waste streams are deposited
- Technology Platform: microorganisms
- Research Business Model: own development, partially public funding, partner funding
- Commercial Model: flexible, dependent on partner and options for BRAIN (options: royalty, license, JV or franchise system)

NBD Deep Dive, The Pipeline

Small Market Potential




Natural Beverage 1

- Partners: Suntory
- Scope: nature based low calorie drink innovation through fermentation
- Exclusive to Suntory, in a certain field
- Technology Platform: microorganism/starter cultures
- Research Business Model: milestone payments
- Commercial Model: starter cultures, license fee, royalties
- In market pre-launch

Salt Taste Enhancer 1.0

- Partners: US-Consumer Packed Goods Company
- Scope: salt reducing taste enhancement via taste modulation
- Exclusive development with partner for one identified molecule
- Technology Platform: BioActive
- Research Business Model: fee, milestone payment (research phase finalized)
- Commercial Model: royalties
- Launch expected 2022

NBD Deep Dive, The End-Markets



¹ Fortune Business Insights; 05/2020, ² Industry Research; 08/2020 ³ Coherent Market Insights; 08/2020 ⁴ Industry statsreport BMRC; 01/2020 ⁵ Global Market Insights, 07/2020 ⁶ Markets and Markets, PR Newswire, 04/2020



Service Business Deep Dive

Programs with industry partners

- BRAIN Biotech AG has a long track record with dedicated contract R&D programs
- Monetization: tech-access, fees and milestone payments, royalties or entity formation/profit participation
- **Non-cyclical service contract business with secular growth**

Tailor Made Solutions (TMS)

Novel natural products & solutions for the industry

- Partnered projects with the industry
- Active NBD sales approach
- Cost-plus contracts, milestones & license fees
- Cross selling of IP to non-exclusive areas
- Strong industry network with over 100 collaborations completed
- Deep and broad knowledge in enzymes, microorganisms and bioactive natural compounds
- Focus areas: nutrition, health and the environment
- From lab to production
- Multi-year contracts

Libraries Business

BioArchive – industry leading collection of natural resources and metagenome libraries

- MetXtra™: unique in silico enzyme selection (Biocatalysts)
- ABEL®: Activity-Based Expression Libraries (BRAIN Zwingenberg)
- LIL®: Large Insert Libraries (BRAIN Zwingenberg)
- METAGENOME®: substantial metagenome libraries (BRAIN Zwingenberg)
- CompActives®: easily scalable compounds for bioactivity screenings (BRAIN Zwingenberg)
- MEGx: world's most sustainable collection of purified natural products, isolated from plants (MEGxp) and microorganisms (MEGxm) (AnalytiCon Discovery)

↑ _____ Strong link & interaction _____ ↑

Partnerships „BRAIN Inside“












More than 100 exclusive partner collaborations successfully completed

| |  <p>Speciality Enzymes</p> |  <p>High-performance Microorganisms</p> |  <p>Bioactive Natural Compounds</p> |
|---------------------|--|--|---|
| Industrial Partner* |  |  |  |

*confidential partnerships not disclosed

Partnerships „BRAIN Inside“

Novel Solutions with high value added for our partners

| |  Speciality Enzymes |  High-performance Microorganisms |  Bioactive Compounds |
|---------------------------|---|--|---|
| Product range |   |  |  |
| BRAIN inside | <p>Low temperature detergent enzymes</p> <p>Flavorpro™ 786P Flavor creation in cheese processing</p> | <p>Optimisation of microbial strain for Isomalt production</p> | <p>Beiersdorf Eucerin</p> <p>Skin anti-irritant Symstitute 1609</p> |
| Industrial partner |   <p>#3 detergent business globally</p> <p>BRAIN subsidiary</p> |  <p>#1 European sugar company</p> |  <p>#4 ingredients supplier globally</p> |

Enzyme Production, Expression Hosts

For expression hosts, a wide variety of protein expression systems are available

Enzymes can be expressed in cell cultures of bacteria or yeasts.


Factors for choosing an expression system

- Protein quality
- Functionality
- Regulatory
- Production speed and yield

Biocatalysts and WeissBioTech

- Use either bacteria or yeasts for the recombinant production of the enzyme being manufactured
- Have the ability to perform the fermentation process over a range from 250mL to 10m³ scale
- This makes it possible to efficiently optimize the production yield


Ongoing development & optimization of our expression hosts is key for the cost competitiveness of our products. In-licensing is also under consideration.



*source: Biocatalysts

Enzyme Production, Expression Hosts

Strain Development: Setting the Scene



We Cover the Entire Enzymes Value Chain


All steps are underpinned by strong customer application knowledge



Discovery



Protein and Enzyme Engineering



Expression/Secretion: Bioprocesses & scale-up




Large Scale Fermentation



Formulation And Blending




Marketing and Sales



Bolt-on M&A can further help strengthen our offering

SolasCure Ltd.

Revolutionizing Chronic Wound Care through Biomimicry



SolasCure

For BRAIN:

- Discovering a unique technology and spinning it out in 2017 as a separate company
- 41% shareholding of BRAIN Biotech AG, at equity consolidated
- Created a targeted team at SolasCure Ltd.
- Share the commercialization financing burden with new investors
- Allows monetization at exit (e.g. IPO, Strategic Investor, PE)
- Aurase® IP stays with BRAIN Biotech AG, (patent estate, WO 2010/099955)

The Market:


- Chronic wounds effect about 40mln people and consume about 10% of health care expenditures
- Advanced wound care market CAGR expected at 6,5% '18-26* (aging, diabetes and obesity are the main growth drivers)
- Alternative to ineffective and painful surgical or autolytic debridement
- Current target market size ~€600mln

The Product:

- Aurase® is a hydrogel containing a safe, active, highly specific enzyme
- The enzyme has been isolated and cloned from medical maggots (green bottle fly)
- Currently phase 2 of clinical trials
- Aurase® to be produced in a GMP biotechnological process
- Santyl® of S&N is currently the market leading drug for non-surgical wound debridement

Latest Funding, Q1 '21

- GBP 3 Mio in total
- New investor attracted: Seneca Partners (VC) with Seneca Growth Capital VCT
- BRAIN participated below pro-rata stake
- Pre-Money valuation +20% versus last capital injection
- BRAIN invested GBP 0.5 Mio
- New partner attracted
- Valuation keeps rising despite Covid-19 related delays



*allied market research '19



BRAIN BioArchive – Nature's Toolbox

~ 53,000

Characterized
Microorganisms

~ 13,000

Plant fractions
available for isolation
campaigns

54

Metagenome
libraries

450

Habitat collections
and environmental
samples

~ 13,000

Plant fractions available
for isolation campaigns

231

Giga-bp DNA ready
to screen

464

Gene libraries
available for
screening

~ 50,000

Natural and naturally
inspired compounds

~ 300 Mio.

Reusable
ready-to-screen
Metagenome clones




High Value:

- ✓ >450 person years to reproduce
- ✓ ~175 patents
- ✓ ~40 patent families
- ✓ Powering TMS, NBD & product sales

BRAIN BioArchive – Nature's Toolbox

A proprietary In-House Screening Resource



R&D / Technology Platforms – Industrial Biotechnology Toolkit



Bio-based resources

BioArchive – industry leading collection of natural resources and metagenome libraries

- MetXtra™: unique in silico enzyme selection (Biocatalysts)
- ABEL®: Activity-Based Expression Libraries (BRAIN Zwingenberg)
- LIL®: Large Insert Libraries (BRAIN Zwingenberg)
- METAGENOME®: substantial metagenome libraries (BRAIN Zwingenberg)
- CompActives®: easily scalable compounds for bioactivity screenings (BRAIN Zwingenberg)
- MEGx: world's most sustainable collection of purified natural products, isolated from plants (MEGxp) and microorganisms (MEGxm) (AnalytiCon Discovery)



Product development

Microbial expression – large set of pro- and eukaryotic expression strains, termed chassis, for the economic production of enzymes and biocatalysts

Microbial strain development – tailor-made designer strains based on conventional methodologies, plus engineering novel synthetic pathways and artificial operons for high-value industrial production

Gene and protein engineering – expression of genes and gene clusters for rationally redesigned production strains, including synthetic biology application, for customized enzymes and biocatalysts with optimized properties



Candidate discovery

High-throughput isolation – extraction and purification of natural products from variable biological resources (AnalytiCon Discovery)

Compound discovery – activity- and sequence-based screenings for application-driven research incl. biochemical and human cell-based assays

- screenline®: human cell-based receptor cell lines (BRAIN)

Structure elucidation – determination of molecular structure of (novel) natural compounds

Sample provision – rapid production of selected enzyme samples for customer testing

- Research Grade Sample (RGS): small volume enzyme sample production platform (Biocatalysts)
- Design for Manufacture (DFM): selection principles of enzyme candidates to maximise the probability for high expression in vivo and production scale-up (Biocatalysts)



Production scale-up

Process development – establishment of up- and downstream processes for efficient and cost-effective microbial production

Process optimization – identification of optimal parameters for superior production results

Product blending & formulation – superior knowhow for blending enzymes



Data evaluation

Analytics – state of the art equipment up to implementation of quality and stability control; covering proteins, metabolites and synthetic compounds

Bioinformatics – top-modern bioinformatic technologies for read-out of Next Generation Sequencing (NGS) results, Design of Experiments (DOE), big data analysis



HR: People – Our Core Capital*

BRAIN is a Knowledge Driven Enterprise

Innovation is our Passion & Teamwork our Basis

- Strong corporate culture
- Technology campus
- Global scientific and university network
- BRAIN alumni platform

~39

years average age

9

years average tenure

54%

female employees

8

trainees

55%

Academics

~ 7%

Average fluctuation since '04



strong support for PhD and
master theses

23%

PhDs



equal pay policy

* numbers refer to BRAIN Biotech AG



Detailed Management & Employee Incentives

- ✓ **Since the IPO BRAIN Biotech AG's board as well as management compensation has been linked and aligned with shareholder interests**

Executive Board

(Fix + performance based bonus)

variable component based on individual quantitative & qualitative targets
stock component, see ESOP

CoPerBo

Corporate Performance Bonus

- ❖ Since FY 2015/16
- ❖ For all employees without personal targets
- ❖ Annual bonus based on basic salary
- ❖ Three factors, 1/3 each
 - Total operation performance BioScience
 - Adj. EBITDA BioScience
 - Absolute share price performance in FY
- ❖ Payout range between 0-30% of basic salary

ESOP


Employee Stock Ownership Program

- ❖ Since June 2018
- ❖ Board, managers and employees
- ❖ Incentive and retainer
- ❖ 1 Option = 1 Share at exercise price
- ❖ Strike price €20,67 and €10.64 from ESOP 2017 and 2018
- ❖ Beneficiary needs to still be employed
- ❖ Earliest exercise day, 4 years after grant
- ❖ Caps partially in place
- ❖ Monte Carlo model applied for fair value calculation
- ❖ 437,600 options outstanding as of Sept.30th 2019

Specific Incentives at Daughter Companies

- ❖ Growth equity program Biocatalysts Ltd.
 - Incentivize and retain managers
 - Share program without voting or dividend rights
 - Put option based on reporting Sept. 30th, 2022
 - Growth incentive with pre-defined EBITDA multiples
 - Cash settled, €17.07 value/share as of September 30th, 2019
- ❖ Employee share scheme, AnalytiCon Discovery
 - Put options for employees and management until February 2020
 - Remuneration in 3 tranches
 - Ownership now at 100%

Peers by Business Activity




*peers by business model




Detailed Financials – Organic vs. Reported




Long-term reported revenues per segment



Long-term organic revenues per segment



Detailed Financials – Expenses Development



Detailed Financials – Adjusted vs. Reported

For a like-for-like comparison BRAIN Biotech AG adjusts its EBITDA for its employee stock ownership program, performance based numeration in daughter companies, acquisition & integration costs

| (in € thousand) | 12M 20/21 | 12M 19/20 |
|--|-----------|-----------|
| EBITDA | -2,533 | -3,876 |
| Gain on bargain purchase | 858 | 0 |
| Share-based employee compensation | -989 | -629 |
| Acquisition and integration costs incurred in the expansion of the BRAIN Group | -313 | -222 |
| Board Changes & Corona Bonus | 0 | -1,007 |
| Adjusted EBITDA | -2,089 | -2,018 |


Detailed Financials – Financial Debt vs. Financial Liabilities

For or a detailed analysis of our EV calculation, our financial liabilities include:


| €thousands | Sept 30th, 2021 | Comment |
|---|-----------------|--|
| Liabilities from put option rights | 4,401 | Biocatalysts Ltd. Call/Put options '23/'24, earlier exercise possible, currently 80.65% ownership |
| Non-controlling shareholders' put option rights | 6 | |
| Contribution by silent partners | 4,526 | €1.5mln Hessen Kapital I GmbH, €3.0mln Hessen Kapital II GmbH, Hybrid Instruments (silent participation) |
| Sum I | 8,933 | |
| Loans | 4,721 | €2.5mln secured by Brain AG, Biocatalysts & L.A. Schmitt land charges |
| Finance Lease Liabilities | 6,655 | mostly plant & equipment |
| Derivatives | 0 | mostly FX hedging |
| Other | 9 | |
| Sum II | 11,385 | |
| | | |
| Total | 20,318 | |
| | | |
| Cash, 12M | 24,545 | |

Detailed Financials – Balance Sheet

Balance sheet September 30, 2021 vs September 30, 2020



Balance sheet September 30, 2021 vs September 30, 2020




M&A Criteria & History

Qualitative mid-term M&A criteria

- B2B only
- Clearly focused on the product business
- Niche applications and producers
- Europe focused, US might be an option

Quantitative mid-term M&A criteria

- Bolt-on character
- Profitable or at least break-even
- Value accretive within 1-2 years post synergies
- Realize economies of scale



Brain AG M&A Transactions

Purchases

| Target | Time | Description | Comment |
|----------------------|------|-------------------------------------|---|
| L.A.Schmitt | 2009 | B2B cosmetics | |
| Monteil Cosmetics | 2012 | B2C cosmetics | |
| AnalytiCon Discovery | 2013 | Library, TMS, R&D | |
| WeissBioTech | 2014 | enzyme design & production | |
| Biocatalysts | 2018 | enzyme design & production | 65.55% owned, put/call options in place |
| BioSun | 2020 | distributor, formulator and blender | |
| Biocatalysts | 2021 | enzyme design & production | stake increased to 82.2%, put/call options in place |

Disposals

| Asset | Time | Description | Comment |
|-------------------|------|---------------|-------------------------------------|
| Monteil Cosmetics | 2019 | B2C cosmetics | refocus of Brain on the B2B segment |

Management CV – Executive Board



Adriaan Moelker (CEO)

- Master of Business Administration
- Year of birth 1964
- Joined BRAIN in 2020
- 20+ y of professional experience in industrial biotechnology innovation
- Successful in terms of innovation & revenue
- Extensive global experience in all key industrial enzyme segments



Lukas Linnig (CFO)

- B.S. in Economics, CFA
- Year of birth: 1993
- Joined BRAIN in 2015
- 7+ y leadership experience in finance, controlling and legal
- Successful in implementing finance controlling systems
- Prior to BRAIN: VC and consulting
- Advisor during the IPO

Management CV – Selected Senior Management



Dr.-Ing. Ute Dechert
(VP HR & Processes)

- Doctor of Engineering (Biochemistry)
- Joined BRAIN in 1996
- 20+ y of professional experience in project management, grant management, HR, organization & processes
- Active ASIIN e.V., Bergstrasse HR Network, University of Esslingen, Provdis University



Dr. Michael Krohn
(EVP, Head of R&D)

- PhD Molecular Biology
- Joined BRAIN in 1997
- 20+ y of leadership experience in BioActives, functional ingredients, contract research, business development
- Coordination NatLifE 2020
- Since 2013 member of the BRAIN Biotech AG executive committee



Dr. Martin Langer
(EVP, Head of Business Development)

- PhD, Molecular Biologist & Biochemist
- Joined BRAIN in 1995
- 25+ y of professional experience in business development, marketing, communication and VC
- Since 2013 member of the BRAIN Biotech AG executive committee

Analyst Coverage

| Bank | Analyst | Target Price | Recommendation |
|--|---------------------------|--------------|----------------|
|  | Markus Mayer | 20.50 € | Buy |
|  | Falko Friedrichs/Jan Koch | 13.00 € | Buy |
|  | Dr. Mohamad Vaseghi | 15.50 € | Buy |
|  | Damien Choplain | 12.50 € | Buy |
|  | Dr. Christian Ehmann | 22.00 € | Buy |

Glossary I

| | |
|--|--|
| Aurase® | Enzymatic agent as part of an innovative gel-based medical device for the biotherapeutic treatment of chronic wounds |
| Bioactive natural compounds | Used to develop products for the food, beverages, skin care, cosmetics and chemical industries |
| Bio-based | Bio-based products are goods manufactured from renewable raw materials |
| Biocatalysts | Enzymes that act as catalysts to accelerate (bio)chemical reactions |
| Biocatalysts Ltd. and Biocatalysts Inc | BRAIN subsidiaries based in UK (headquarters in Cardiff, Wales) and subsidiary in US (Illinois); global distributor network e.g. Korea, Australia, New Zealand. Key player in the specialty enzyme business |
| Bioeconomy | Concept for a biobased economy; mega-trend that encompasses the transformation from industries based on fossil raw materials to a more sustainable form of economic activity that mainly utilizes biological resources and processes |
| BioIndustrial | One of BRAIN's two business segments: development and marketing of the company's own products along the value chain |
| Biologization of industry | Application of biological processes in an industrial setting with the aim of creating a more sustainable economy |
| Biorefinery | <p>Technology for the sustainable processing of biomass into marketable products (e.g. food, feed, materials, chemicals) and energy (fuels, electricity, heat).</p> <p>Integrated biorefineries combine various such technologies with the aim of greater flexibility and cost reduction. Integrated biorefineries facilitate the use of byproducts and waste, and enable the production of high-quality products (e.g. fine chemicals) combined with low-quality products (e.g. bioenergy).</p> |
| BioScience | One of BRAIN's two business segments: cooperation business established with globally operating industrial partners |

Glossary II

| | |
|----------------------------|---|
| Biotechnology | Application-oriented sub-sector of biology; includes insights and methods from microbiology, genetics, biochemistry, technical chemistry and process engineering; utilizes biological processes e.g. for industrial applications |
| BEC | BRAIN Engineered Cas: BRAIN's first proprietary non-Cas9 genome editing nuclease |
| BioXtractor | BRAIN demonstration plant for next-generation metal extraction in the areas of green and urban mining based on microorganisms |
| BRAIN Bioarchive | In-house collection consisting of around 53,000 comprehensively characterized microorganisms (including "chassis microorganism" strains for the development of production organisms) and the BRAIN libraries: an enzyme library, a metagenome library and a substance library with numerous isolated natural compounds (see also BRAIN libraries) |
| BRAIN Libraries | <p>BRAIN Group collections of enzymes, DNA sequences or natural substances</p> <p>Enzyme library: up to 500 isolated and pre-characterized enzymes and DNA coding for enzymes introduced into expression vectors</p> <p>Metagenome library: screenable DNA library with metagenomes from different habitats; collection serves to identify previously uncharacterized enzymes and metabolic pathways</p> <p>Substance library: collection of natural substances with sub-libraries of specific, well-characterized groups of substances</p> |
| BMC | BRAIN Metagenome Cas: BRAIN's second proprietary non-Cas9 genome editing nuclease |
| Bulk enzymes markets | Volume-driven mass markets for enzymes sold in large volumes. This stands in contrast with the high-margin business with specialty enzymes |
| Business-to-Business (B2B) | Form of the market in which the supply and rendering of services is realized by companies to companies (= business relations between at least two companies) |
| Cas | CRISPR associated sequence |

Glossary III

| | |
|----------------------|---|
| Circular bio-economy | Term derived from the fusion of the two concepts of the “bio-economy” and the “circular economy”; circular bio-economy focuses on the sustainable, resource-efficient utilization of biomass in integrated production chains (e.g. biorefineries) while BRAIN demonstration plant for next-generation metal extraction in the areas of green and urban mining based on microorganisms simultaneously utilizing residual and waste materials; the sequential use (cascade use) of biomass resources for different purposes ensures value optimization. |
| Circular economy | Concept for the complete recovery of raw materials utilized, beyond a commodity’s life cycle, through to new production processes; component of the bioeconomy |
| Clone | Genetically identical organisms, created by natural division or reproduction, or artificially created |
| Compliance | Alignment of companies with laws and directives, as well as voluntary codes |
| CRISPR | Clustered regularly interspaced short palindromic repeats |
| CRISPR-Cas | systems have enabled genome editing in multiple species and provided genetic tools with speed as well as simplicity that were previously unavailable |
| Development pipeline | Total number of BRAIN Group development projects for New Business/Product Development |
| Development projects | R&D projects of the BRAIN Group for New Business/Product Development |
| DNA | Deoxyribonucleic acid: biomolecule that carries genetic information (genes) |
| DOLCE | Strategic partnership initiated by BRAIN for the development of natural sweeteners and sweet taste enhancers |
| Editing | requires only two components (1. Cas nuclease 2. programmable guide RNA), and can be multiplexed for simultaneous modification of multiple sites in a single transformation event |

Glossary IV

| | |
|---------------------------------|---|
| Enzymes | Proteins that accelerate biochemical reactions in their function as biocatalysts; play an important role in the development of biobased products; BRAIN identifies and develops optimized enzymes and biocatalysts for complex process and application requirements |
| FRESCO | BRAIN development program for freshness and product stability utilizing natural bioactive substances; suitable for the food and feed industry, for medical products, paints, cleaning agents and other household products |
| Genome Editing | Directed and precise change or use of a chromosomal target in a given organism; “the power to program cells” |
| Giga-bp DNA | Length of a DNA sequence, indicated by the number of base pairs (1 Giga bp = 1,000,000,000 base pairs); common metagenomics measure |
| GRAS status | Generally Regarded as Safe status: declaration of safety for the use of substances (e.g. microorganisms) to manufacture foodstuffs; GRAS organisms can be utilized without restriction in biotechnological production |
| Green mining | Sustainable mining, e.g. ore treatment to extract gold, silver or copper using microorganisms rather than chemicals |
| Habitat | An organism’s natural environment |
| High-performance microorganisms | Biotechnologically optimized microorganisms that serve as microbial “cell factories” |
| HTC technology | Human Tongue Cell Technology; in vitro test system based on human tongue cells, established and patented by BRAIN to test substances for their sweetening power |
| Industrial biotechnology | Also known as white biotechnology; drives innovation for a paradigm shift away from petroleum-based towards biological processes and bioeconomy products |
| Metagenome | All the genomic information present in all the microorganisms of a specific community |
| Metagenomics | Genomic analysis of a community of organisms by gene sequencing; genetic material is extracted, sequenced and analyzed directly from environmental samples, which saves the previous cultivation of microorganisms |

Glossary V

| | |
|--------------------------------|---|
| Microorganism | Microscopically small unicellular or multicellular organisms, e.g. bacteria, algae, fungi or viruses |
| New Business Development (NBD) | Systematic further development of existing and development of new business opportunities including e.g. R&D and marketing activities |
| New Product Development (NPD) | R&D activities that aim to develop product candidates for the BRAIN Group's own market offerings |
| Peptides | Linear, sometimes ring-shaped chain of molecules consisting of two or more amino acids; long polypeptide chains are called proteins. |
| Product sales | Sales of products in the fso known as white biotechnology; drives innovation for a paradigm shift away from petroleum-based towards biological processes and bioeconomy productsorm of merchandise, technologies or biotechnological system solutions; can be achieved via the BRAIN Group's direct B2B business or through joint product developments with industrial partners and corresponding licensing agreements; scalable-product business option offered by the BRAIN Group (see also R&D cooperation partnerships) |
| R&D | Research and development |
| SALT-E | BRAIN development program for healthier foods through salt reduction |
| SDG-UN | United Nations Sustainable Development Goals |
| Specialty chemicals | Specific chemical products with a broad range of activities on which a large number of other industrial sectors depend |
| Synthetic Biology | Area of biology in which organisms are modified to develop new, useful abilities |
| Specialty enzymes market | Markets for high-margin specialty enzymes business |

Glossary VI

| | |
|------------------------------|---|
| Tailor-Made-Solutions TMS | Dedicated contract R&D programs for the development of tailor-made solutions for industry |
| Urban mining | Sustainable extraction of valuable substances from secondary raw materials and waste flows in order to retain them in value chains in the long term |
| White Biotechnology | Includes the application of modern biotechnology in industrial production processes. Chemical starting materials are converted by enzymes and cells into products suitable for further processing. Also known as industrial biotechnology |

